VYxeoS Liposomal Italian Observational Study iN the Real Practice
The study is a prospective, single-arm, non-experimental, observational study in patients in Italy with Acute Myeloid Leukaemia (AML) with myelodysplastic-related changes or therapy related AML initiating treatment with JZP351 (Vyxeos liposomal) in their normal clinical practice.
Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia With Myelodysplasia-Related Changes|Therapy-Related Acute Myeloid Leukemia
DRUG: Vyxeos liposomal
Percentage of participants showing CR/CRi/CRh without MRD at the end of treatment, Percentage of participants showing CR (Complete Remission) / CRi (Complete Response with incomplete platelet or neutrophil recovery) /CRh (Complete Response with partial hematologic recovery) without MRD (measurable residual disease) at the end of treatment. MRD will be assessed via multiparameter flow cytometry., Up to 24 months
Overall Response Rate (ORR) after induction phase, ORR is the rate of participants achieving CR, CRi and CRh after induction phase, Up to 24 months|Percentage of participants showing CR/CRi/CRh without MRD after induction phase, MRD will be assessed via multiparameter flow cytometry., Up to 24 months|Percentage of participants showing CR/CRi/CRh without MRD before transplantation, MRD will be assessed via multiparameter flow cytometry., Up to 24 months|Overall survival (OS), Overall survival is date from the start of taking Vyxeos liposomal (JZP351) to the date of reported death due to any cause., Up to 24 months|Percentage of participants receiving an Hematopoietic stem-cell transplantation (HSCT), Up to 24 months|Landmark overall survival (OS) from the time of HSCT, Up to 24 months|Percentage of participants with Adverse Events (AE), Percentage of participants who experience Grades 1-5 and grade 3-5 adverse events, including AEs of special interest and serious AEs (SAEs), as evaluated by treating physician., Up to 24 months|Percentage of participants with a change in fitness status as assessed by Ferrara criteria before HSCT, Ferrara criteria is a list of assessments evaluating whether a participant is eligible for intensive chemotherapy or not., Up to 24 months|Percentage of participants with a change in fitness status as assessed by Ferrara criteria at the final treatment visit for patients not eligible for HSCT, Ferrara criteria is a list of assessments evaluating whether a participant is eligible for intensive chemotherapy or not., Up to 24 months
The study is a prospective, single-arm, non-experimental, observational study in patients in Italy with Acute Myeloid Leukaemia (AML) with myelodysplastic-related changes or therapy related AML initiating treatment with JZP351 (Vyxeos liposomal) in their normal clinical practice.